Bendroflumethiazide

Bendroflumethiazide

Systematic (IUPAC) name
3-Benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4- benzothiadiazine-7-sulfonamide
Clinical data
AHFS/Drugs.com	Consumer Drug Information
Pregnancy category	Risk neonatal thrombocytopenia in 3rd trimester[1]
Legal status	UK: Prescription-only (POM)
Routes of administration	Oral
Pharmacokinetic data
Bioavailability	100%
Protein binding	96%
Metabolism	extensive
Half-life	3-4 hours[2]
Identifiers
CAS Registry Number	73-48-3 Y
ATC code	C03AA01
PubChem	CID 2315
DrugBank	DB00436 Y
ChemSpider	2225 Y
UNII	5Q52X6ICJI Y
KEGG	D00650 Y
ChEBI	CHEBI:3013 Y
ChEMBL	CHEMBL1684 Y
Chemical data
Formula	C15H14F3N3O4S2
Molecular mass	421.415 g/mol
SMILES FC(F)(F)c3c(cc1c(NC(NS1(=O)=O)Cc2ccccc2)c3)S(=O)(=O)N
InChI InChI=1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)  Y Key:HDWIHXWEUNVBIY-UHFFFAOYSA-N  Y
Y (what is this?)  (verify)

Bendroflumethiazide (INN), formerly bendrofluazide (BAN), trade name Aprinox, is a thiazide diuretic used to treat hypertension.

Bendroflumethiazide is a thiazide diuretic which works by inhibiting sodium reabsorption at the beginning of the distal convoluted tubule (DCT). Water is lost as a result of more sodium reaching the collecting ducts. Bendroflumethiazide has a role in the treatment of mild heart failure although loop diuretics are better for reducing overload. The main use of bendroflumethiazide currently is in hypertension (part of the effect is due to vasodilation).

Common adverse effects:

• postural hypotension
• hyponatraemia, hypokalaemia, hypercalcaemia
• gout
• impaired glucose tolerance
• impotence

Rare adverse effects:

• thrombocytopenia
• agranulocytosis
• photosensitivity rash
• pancreatitis

References